Table 3. Markers influencing time to first PE during stable disease.
| Marker | Hazard ratio1 | 95% hazard ratio confidence limits | p-value | |
| Clinical assessment | FEV1% predicted | 0.97 | 0.94–0.99 | 0.006 |
| FVC% predicted | 0.97 | 0.95–0.99 | 0.010 | |
| Matouk Disease Score | Clinical | 0.74 | 0.63–0.86 | 0.000 |
| PFT | 0.88 | 0.80–0.98 | 0.015 | |
| CXR | 0.71 | 0.50–0.94 | 0.017 | |
| Complication | 1.33 | 1.17–1.51 | 0.000 | |
| Total | 0.92 | 0.88–0.96 | 0.000 | |
| Quality of life | Weight | 0.97 | 0.95–0.99 | 0.006 |
| Respiratory | 0.96 | 0.92–0.99 | 0.024 | |
| Physical | 0.96 | 0.93–0.99 | 0.003 | |
| Vitality | 0.96 | 0.93–1.00 | 0.043 | |
| Health perceptions | 0.95 | 0.92–0.99 | 0.005 | |
| Role | 0.96 | 0.94–0.99 | 0.020 | |
| Total | 0.99 | 0.99–1.00 | 0.004 |
1
HR<1 is associated with lower risk of future PE.